Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-U01 Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Hematologic Malignancies or Solid Tumors
jRCT2031250824Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of zilovertamab vedotin in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) and 2 more, sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicity in Part 1, Adverse events in Part 1 and 4 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)neuroblastomaEwing sarcoma
Beyond the preview
Go deeper on jRCT2031250824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250824.